Drug Development

Hollis-Eden Pharmaceuticals Reports on Progress in Drug Development Programs; Announces Second Quarter 2007 Financial Results

Published in Healthcare Finance, Tax and Law Weekly, August 22nd, 2007

Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH), the leader in the development of a new class of small molecule compounds based on endogenous steroid hormones, reported on its progress and outlook for the Company's drug development programs in the areas of metabolic disorders, inflammatory conditions and cancer, and announced financial results for the second quarter of 2007.

Recent Progress in Drug Development Programs

Keywords: Drug Development, Hollis-Eden Pharmaceuticals Inc., Pharmaceutical Business, Pharmaceutical Company, Therapy, Treatment, Hollis-Eden Pharmaceuticals Inc.

This article was prepared by Healthcare Finance,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Healthcare Finance, Tax and Law Weekly

Source: Healthcare Finance, Tax and Law Weekly (2007-08-22)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry